KOD stock forecast, quote, news & analysis
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines... Show more
Why Kodiak Sciences (KOD) Is Up +39% in the Last 30 Days
Key Takeaways
- KOD stock surged +39% over the past 30 days, driven primarily by positive Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy.
- Over the past quarter, shares gained +36%, reflecting anticipation of clinical catalysts and a successful $184 million capital raise.
- Analyst upgrades and raised price targets from firms like UBS, H.C. Wainwright, and Jefferies followed the trial success, boosting sentiment.
- Biotech sector trends and strong pipeline progress, including upcoming readouts for wet AMD, supported the upward momentum.
- Volatile trading post-news, with a 75% single-day spike on March 26, tempered by profit-taking.
Kodiak Sciences (KOD) Company Overview and Market Position
Kodiak Sciences Inc. (KOD) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases, major causes of vision loss. Its proprietary Antibody Biopolymer Conjugate (ABC) platform enables sustained-release treatments, aiming to reduce injection frequency compared to standard anti-VEGF therapies. The lead candidate, Zenkuda (tarcocimab tedromer, KSI-301), targets conditions like diabetic retinopathy (DR), wet age-related macular degeneration (AMD), and retinal vein occlusion. Additional pipeline assets include KSI-501, a bispecific for inflammation and vascular issues, and KSI-101 for macular edema secondary to inflammation (MESI).
In the competitive ophthalmology market dominated by Roche's Lucentis and Regeneron/Eylex's Eylea, Kodiak's durable formulations address unmet needs for less frequent dosing. Recent clinical successes have strengthened its position, explaining the stock's rally amid positive data and funding.
Kodiak Sciences (KOD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, KOD stock rose +39%, from a close of $27.36 on March 2 to $37.99 on March 31. The movement was volatile and trend-driven, trading range-bound around $22-$28 until a explosive +75% surge on March 26 to $39.76, followed by consolidation with gains on March 31.
For the quarter, shares advanced +36%, from $27.96 at year-end 2025 to $37.99. Performance featured early-year dips to the low $20s, steady recovery, and acceleration on pipeline news, marking an uptrend with heightened volume during catalysts.
What Drove KOD Stock Price in the Last 30 Days
The dominant catalyst was Kodiak's March 26 announcement of positive topline results from the Phase 3 GLOW2 study of Zenkuda in diabetic retinopathy. The drug demonstrated superiority over sham, with 62.5% of treated patients achieving a ≥2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS), versus 3.3% in controls (p<0.0001), and an 85% risk reduction in progression. This durability on a 6-month interval fueled a 68%-75% single-day surge, the highest in over four years.
Analysts responded swiftly: UBS raised its target to $80 from $50, H.C. Wainwright to $58 from $38, and Jefferies to $56 from $39, citing accelerated BLA potential. Market sentiment shifted positively in biotech ophthalmology, amplifying the move amid high volume exceeding 13 million shares on March 26.
What Drove KOD Stock Performance Over the Last Quarter
The quarter's +36% gain built on sustained narratives around Kodiak's pipeline reboot post-2023 setbacks. Key was a $184 million equity offering in December 2025, extending cash runway into 2027 and reducing dilution fears. Anticipation for GLOW2 and other Phase 3 readouts like DAYBREAK for wet AMD drove steady climbs from January lows near $22.
Macro biotech recovery, institutional interest (high ownership noted), and competitive positioning against frequent-injection rivals bolstered cumulative impact. Sector trends favoring durable retinal therapies and positive prior GLOW1 data sustained upward pressure, culminating in the late-March breakout.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from among hundreds that analyze thousands of tickers across various markets. These curated bots represent the most relevant and successful performers based on recent trading results, strategies like trend-following, mean reversion, or momentum, and metrics including win rate, profit factor, and Sharpe ratio. Timeframes range from intraday scalping to long-term swings, catering to diverse risk appetites and styles. Investors can explore detailed performance histories, backtests, and live signals to identify bots aligning with their portfolio needs. Check out Trending AI Robots today to enhance your trading edge.
KOD Stock Forecast Drivers: What Investors Should Watch Next
Key monitors include topline data from the Phase 3 DAYBREAK study of Zenkuda in wet AMD, expected Q3 2026, and KSI-501 readouts. BLA submission timelines for Zenkuda across DR, wet AMD, and other indications could accelerate post-GLOW2. Industry trends in retinal therapies, competitor updates like Roche or Regeneron launches, and macroeconomic factors such as interest rates impacting biotech funding remain critical. Strategic developments like partnerships or additional financing, alongside risks from full trial data, regulatory feedback, and cash burn, will shape sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
KOD in -7.99% downward trend, falling for three consecutive days on June 25, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where KOD declined for three days, in of 304 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where KOD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Aroon Indicator for KOD entered a downward trend on June 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KOD's RSI Oscillator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on KOD as a result. In of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for KOD just turned positive on June 15, 2026. Looking at past instances where KOD's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KOD advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .
KOD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KOD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.450) is normal, around the industry mean (21.001). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). KOD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (368.009).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KOD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapies for the treatment of retinal disease
Industry Biotechnology